BioSpace News Archive

2020 revenue of $526 million and fourth quarter 2020 revenue of $135 million 2020 net loss of $75 million and fourth quarter net income of $2.4 million 2020 Adjusted EBITDA 1 of $233 million and fourth quarter 2020

Cardiovascular Systems, Inc. Announces First Uses of WIRION ® Embolic Protection System Device offers a streamlined approach for lower extremity embolic protection

Carmot Therapeutics, Inc. (Berkeley, CA), a clinical stage biotechnology company advancing transformative therapies for patients with metabolic diseases, announced today the appointment of Manu Chakravarthy, MD, PhD as Chief Medical Officer and EVP of R&D, and member of the executive leadership team. “Dr. Cha

Prestigious honor validates potential of Alveo’s low-cost, accessible COVID-19 testing technology as company prepares for commercialization

Cendes honored for contributions to theory, development and commercialization of electromagnetics simulation software

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it will participate in the upcoming 2021 Virtual Wells Fargo Biotech Corporate Access Day.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate in the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC.

- Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month - - Accelerating retail demand drove 73% increase in ex-factory sales month-over-month - - Ex-factory sales YTD 2021 through mid-March have exceeded FY 2020 levels -

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), today announced that results of a post-hoc analysis of data from two Phase 3 clinical trials of pitolisant, a histamine 3 (H3) receptor antagonist/inverse agonist

Amathus Therapeutics announced today a strategic collaboration with Merck, known as MSD outside the United States and Canada, to develop novel small molecule therapeutic candidates for neurodegenerative diseases.